摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-alpha-D-阿拉伯呋喃糖基-2-硝基-1H-咪唑 | 83416-40-4

中文名称
1-alpha-D-阿拉伯呋喃糖基-2-硝基-1H-咪唑
中文别名
麦穗灵
英文名称
1-α-D-(arabinofuranosyl)-2-nitroimidazole
英文别名
1-(α-D-arabinofuranosyl)-2-nitroimidazole;1-α-D-arabinofuranosyl-2-nitroimidazole;α-AZA;1-alpha-D-Arabinofuranosyl-2-nitro-1H-imidazole;(2R,3S,4S,5S)-2-(hydroxymethyl)-5-(2-nitroimidazol-1-yl)oxolane-3,4-diol
1-alpha-D-阿拉伯呋喃糖基-2-硝基-1H-咪唑化学式
CAS
83416-40-4
化学式
C8H11N3O6
mdl
——
分子量
245.192
InChiKey
GEPYEWPQCQPUJN-JWXFUTCRSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    626.0±65.0 °C(Predicted)
  • 密度:
    1.98±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -1.1
  • 重原子数:
    17
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.62
  • 拓扑面积:
    134
  • 氢给体数:
    3
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-alpha-D-阿拉伯呋喃糖基-2-硝基-1H-咪唑 在 palladium on activated charcoal 氢气 作用下, 以 乙醇 为溶剂, 25.0 ℃ 、101.32 kPa 条件下, 反应 2.0h, 以88%的产率得到1-(alpha-D-阿拉伯呋喃糖基)-1H-咪唑-2-胺
    参考文献:
    名称:
    Synthesis of Iodoaminoimidazole Arabinoside (IAIA): A Potential Reductive Metabolite of the Spect Imaging Agent, Iodoazomycin Arabinoside (IAZA)
    摘要:
    The stereospecific synthesis of 1-(5-deoxy-5-iodo-alpha-D-arabinofuranosyl)-2-aminoimidazole (iodoaminoimidazole arabinoside: IAIA, 2) is described. The reaction of the protected sugar bromide (8) and trifluoroacetamidoimidazole (10B) gave the coupled product (11B), which gave the free nucleoside (4) on deblocking. It was identical with AIA obtained by reduction of AZA (azomycin arabinoside), whose anomeric configuration was found to be a by the X-ray crystallography.
    DOI:
    10.1080/07328319908044860
  • 作为产物:
    参考文献:
    名称:
    碘化阿霉素核苷类组织缺氧新标志物的合成和放射性标记。
    摘要:
    已经合成了七种二代碘化阿霉素核苷类缺氧标记物,并在体外和体内测试了肿瘤细胞的缺氧标记活性。β-D-碘阿唑霉素半乳糖苷 (IAZG) 和 β-D-碘阿霉素木吡喃糖苷 (IAZXP) 表现出优于 IAZA 的缺氧标记特性,因为它们具有更高的水溶性、从荷瘤小鼠体内快速清除血浆的速度和最大肿瘤/血液 ( /B) 和肿瘤/肌肉 (T/M) 比率。我们对动物肿瘤模型的研究表明,通过闪烁扫描或平面成像确定的这些标志物的 T/B 或 T/M 比率可以预测肿瘤缺氧的相对程度和肿瘤的放射抗性。© 1997 约翰威利父子公司。
    DOI:
    10.1002/(sici)1099-1344(199707)39:7<541::aid-jlcr5>3.0.co;2-b
点击查看最新优质反应信息

文献信息

  • The synthesis and radiolabelling of novel markers of tissue hypoxia of the iodinated azomycin nucleoside class.
    作者:R. F. Schneider、E. L. Engelhardt、C. C. Stobbe、M. C. Fenning、J. D. Chapman
    DOI:10.1002/(sici)1099-1344(199707)39:7<541::aid-jlcr5>3.0.co;2-b
    日期:1997.7
    Seven second-generation hypoxic markers of the iodinated azomycin nucleoside class have been synthesized and tested for hypoxia marking activity with tumor cells in vitro and in vivo. β-D-lodoazomycin galactoside (IAZG) and β-D-iodoazomycin xylopyranoside (IAZXP) demonstrated superior hypoxia marking properties relative to IAZA because of their higher water solubilities, rapid plasma clearance rates
    已经合成了七种二代碘化阿霉素核苷类缺氧标记物,并在体外和体内测试了肿瘤细胞的缺氧标记活性。β-D-碘阿唑霉素半乳糖苷 (IAZG) 和 β-D-碘阿霉素木吡喃糖苷 (IAZXP) 表现出优于 IAZA 的缺氧标记特性,因为它们具有更高的水溶性、从荷瘤小鼠体内快速清除血浆的速度和最大肿瘤/血液 ( /B) 和肿瘤/肌肉 (T/M) 比率。我们对动物肿瘤模型的研究表明,通过闪烁扫描或平面成像确定的这些标志物的 T/B 或 T/M 比率可以预测肿瘤缺氧的相对程度和肿瘤的放射抗性。© 1997 约翰威利父子公司。
  • Synthesis, radiofluorination, and hypoxia-selective studies of FRAZ: A configurational and positional analogue of the clinical hypoxia marker, [18F]-FAZA
    作者:Piyush Kumar、Ebrahim Naimi、Alexander J. McEwan、Leonard I. Wiebe
    DOI:10.1016/j.bmc.2010.01.064
    日期:2010.3
    work evaluates 1-α-d-(2-deoxy-2-fluororibofuranosyl)-2-nitroimidazole (FRAZ), a novel azomycin nucleoside that is a potential radiosensitizer of tumor hypoxia. FRAZ is a ribose analogue of 1-α-d-(2-deoxy-2-fluoroarabinofuranosyl)-2-nitroimidazole ([18F]-FAZA), a clinically used hypoxia marker. Preliminary assessment of the cytotoxicity and hypoxia-specific in vitro binding in HCT-110 colorectal cancer
    目前的工作是评估1-α- d-(2-脱氧-2-氟核呋喃呋喃糖基)-2-硝基咪唑(FRAZ),一种新型的阿霉素核苷,它是潜在的肿瘤缺氧放射增敏剂。FRAZ是临床上使用的缺氧标记物1-α- d-(2-脱氧-2-氟阿拉伯呋喃糖基)-2-硝基咪唑([ 18 F] -FAZA)的核糖类似物。对HCT-110大肠癌细胞的细胞毒性和低氧特异性体外结合的初步评估表明,FRAZ的放射增敏特性与FAZA相似,增敏剂增强比(SER)为〜1.8。[ 18的自动放射合成建立了使用商用自动合成装置(ASU)的F] -FRAZ(合成时间约32分钟;放射化学收率(无衰减)约22%),以促进其在基于PET的低氧肿瘤诊断中的应用。
  • Nitroimidazole radiosensitizers for hypoxic tumor cells and compositions
    申请人:Research Corporation
    公开号:US04462992A1
    公开(公告)日:1984-07-31
    Compounds of the formula: ##STR1## wherein W is selected from the group consisting of ##STR2## Wherein Q is hydrogen or --CH.sub.2 OR.sup.1 ; Z is hydrogen or --OR.sup.1 ; n is 1 or 2; wherein R.sup.1 are the same or different radicals selected from the group consisting of hydrogen, and ##STR3## where R.sup.2 is lower alkyl, aryl, or aralkyl; wherein the bond at positions 2' and 3' of structure I may be single or double; or it may be a C-nucleoside attached at 3' position of the sugar; X and Y are the same or different selected from the group consisting of hydrogen, an electron withdrawing group, and a group wherein X and Y taken together form a 6-membered carbocylic aromatic ring, are useful as radiosensitizing agents during x-ray radiotherapy of tumor cells.
    公式为:##STR1## 其中W选自以下组合:##STR2## 其中Q为氢或--CH.sub.2 OR.sup.1;Z为氢或--OR.sup.1;n为1或2;其中R.sup.1为氢、##STR3##的相同或不同基团,其中R.sup.2为较低的烷基、芳香族或芳基烷基;结构I的2'和3'位置的键可以是单键或双键;或者可以是连接在糖的3'位置的C-核苷酸;X和Y选自以下组合:氢、电子提取基团和X和Y在一起形成6-成员环烷基芳香环的基团。这些化合物在肿瘤细胞的X射线放疗期间作为放射增敏剂是有用的。
  • Modified hydrocarbon resins as fluid loss additives
    申请人:INGEVITY SOUTH CAROLINA, LLC
    公开号:US10005947B2
    公开(公告)日:2018-06-26
    Methods for treating oil-based drilling fluids with a fluid loss additive that includes one or more hydrocarbon resins. An oil-based drilling fluid and a hydrocarbon resin can be combined to produce a treated oil-based drilling fluid. The hydrocarbon resin can include a polymerized product of a reaction mixture that can include a dicyclopentadiene; at least one member selected from the group consisting of: a dimer of an aliphatic cyclic diene having five carbon atoms, a dimer of an aliphatic non-cyclic diene having five carbon atoms, a monoolefin, a diolefin, or a polyene, each having more than five carbon atoms and no aromatic rings, a C5-olefin, a debutanized aromatic concentrate, and any mixture thereof; and at least one member selected from the group consisting of: a fatty acid-containing material, a rosin acid-containing material, and a mixture thereof.
    用包括一种或多种烃类树脂的流体流失添加剂处理油基钻井液的方法。可将油基钻井液和烃类树脂结合起来,生产出处理过的油基钻井液。烃类树脂可包括反应混合物的聚合产物,该反应混合物可包括双环戊二烯;至少一种选自以下组别的成员:具有五个碳原子的脂肪族环状二烯的二聚体、具有五个碳原子的脂肪族非环状二烯的二聚体、单烯烃、二烯烃或多烯(各自具有五个以上碳原子且无芳香环)、C5-烯烃、去烷化芳香族浓缩物及其混合物;以及至少一个选自以下组别的成员:含脂肪酸的材料、含松香酸的材料及其混合物。
  • WO2006/102759
    申请人:——
    公开号:——
    公开(公告)日:——
查看更多

同类化合物

阿卡地新 咪唑立宾 5'-单磷酸酯 咪唑立宾 [(2R,3S,4R,5R)-5-[4-氨基甲酰-5-[[(3R,4R)-3,4-二羟基-2-氧代-5-膦酰氧基戊基]亚氨基甲基氨基]咪唑-1-基]-3,4-二羟基四氢呋喃-2-基]磷酸二氢甲酯 N-[5-氨基-1-(BETA-D-呋喃核糖基)咪唑-4-羰基]-L-天冬氨酸 5-碘-1-(2’,3’,5’-三-O-乙酰基-beta-D-呋喃核糖基)-咪唑并-4-甲腈 5-甲酰氨基咪唑-4-甲酰胺核苷酸 5-氯-1-[3,4-二羟基-5-(羟基甲基)四氢呋喃-2-基]咪唑-4-甲酰胺 5-氨基-4-咪唑甲酰胺核糖甙 5'-三磷酸酯 5-氨基-1-(2-O,3-O,5-O-三乙酰基-beta-D-呋喃核糖基)-1H-咪唑-4-甲酰胺 5-氨基-1-(2,7-二羟基-2-氧代四氢-4H-呋喃并[3,2-d][1,3,2]二氧杂环己膦烷-6-基)-1H-咪唑-4-甲酰胺 5-乙炔基-1-呋喃核糖基咪唑-4-甲酰胺 4-(羧甲基)-1-(beta-D-呋喃核糖基)-1H-咪唑 2-硝基-1-beta-D-呋喃核糖基-1H-咪唑 1-alpha-D-阿拉伯呋喃糖基-2-硝基-1H-咪唑 1-(alpha-D-阿拉伯呋喃糖基)-1H-咪唑-2-胺 (2S)-2-[[5-氨基-1-[(2R,3R,4S,5R)-3,4-二羟基-5-(膦酰氧基甲基)四氢呋喃-2-基]咪唑-4-羰基]氨基]丁二酸 (2R)-2-环己基-2-羟基-2-苯基乙酸 (1-羟基乙基)-5-甲基-1-beta-呋喃核糖基咪唑 5-amino-1-(β-D-ribofuranosyl)-4-(5-propyl-1,2,4-oxadiazol-3-yl)imidazole 5-amino-1-(β-D-ribofuranosyl)-4-(5-phenyl-1,2,4-oxadiazol-3-yl)imidazole 5-amino-1-(β-D-ribofuranosyl)-4-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]imidazole 5-amino-1-(β-D-ribofuranosyl)-4-(5-ethyl-1,2,4-oxadiazol-3-yl)imidazole 5-amino-1-(β-D-ribofuranosyl)-4-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]imidazole 5-[1-(Dimethylamino)ethylideneamino]-1-[2,3-O-(1-methylethylidene)-β-D-ribofuranosyl]-imidazole-4-carbonitrile 1-(2',3',5'-tri-O-benzoyl-β-D-ribofuranosyl)-4-(3-ureidophenyl)imidazole 5-amino-2-(4-fluorophenyl)-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-2-(3-chlorophenyl)-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-2-(4-methoxyphenyl)-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-2-(2-phenylvinyl)-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-2-phenyl-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-2-(2-furyl)-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-1-β-D-ribofuranosylimidazole-2-(2-thienyl)-4-carboxamide 5-amino-1-β-D-ribofuranosylimidazole-4-carboxamideoxime hydrochloride acadesine-5’-O-bis(benzoxy-L-alaninyl)phosphate 5-diazonium-1-β-D-ribofuranosyl-1H-imidazole-4-carboxamide 5-amino-1-(3-O-methyl-β-D-ribofuranosyl)imidazole-4-carboxamide 5-amino-1-(3-O-n-butyl-β-D-ribofuranosyl) imidazole-4-carboxamide 5-amino-1-(3-O-ethyl-β-D-ribofuranosyl)-4-imidazole carboxamide 5-amino-1-(2-O-ethyl-β-D-ribofuranosyl)-4-imidazole carboxamide N4-(benzyl) AICAR triphosphate N1-<(β-D-Ribosyl)formimino>-5-aminoimidazole-4-carboxamide ribonucleotide N1-<(5''-Phospho-β-D-ribosyl)formimino>-5-aminoimidazole-4-carboxamide ribonucleoside N1-<(β-D-Ribosyl)formimino>-5-aminoimidazole-4-carboxamide ribonucleoside 2-Benzyl-1-(β-D-ribofuranosyl)imidazol-4,5-dicarboxamid 4-N-[(S)-pyrrolidine-2-carbonyl]amino-1-β-D-ribofuranosylimidazole 5-amino-1-(β-D-ribofuranosyl)-4-(5-pentyl-1,2,4-oxadiazol-3-yl)imidazole 5-amino-1-(β-D-ribofuranosyl)-4-(5-heptyl-1,2,4-oxadiazol-3-yl)imidazole acadesine-5’-O-bis(methoxy-L-alaninyl)phosphate 4,5-dichloro-1-(β-D-ribofuranosyl)imidazole